广济药业(000952) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥133,421,305.86, a decrease of 26.25% compared to ¥180,917,718.37 in the same period last year[8] - The net profit attributable to shareholders was a loss of ¥13,243,999.35, representing a decline of 143.54% from a profit of ¥30,418,048.31 in the previous year[8] - Operating profit was -13,297,645.86, representing a decline of 135.35% year-over-year[17] - Net profit was -15,044,467.90, a decrease of 150.40% compared to the previous year[17] - The basic earnings per share for the reporting period was -¥0.053, down 143.44% from ¥0.122 in the same period last year[8] - The total comprehensive income for Q1 2020 was a loss of CNY 15,037,111.97, compared to a profit of CNY 29,836,796.11 in the previous year[42] Cash Flow - The net cash flow from operating activities increased significantly by 298.97%, reaching ¥28,404,655.29 compared to ¥7,119,509.04 in the same period last year[8] - Cash inflow from operating activities totaled ¥141,356,972.17, compared to ¥169,985,894.90 in the previous year, reflecting a decrease of about 17%[49] - Cash outflow from operating activities was ¥112,952,316.88, down from ¥162,866,385.86 in Q1 2019, indicating a reduction of approximately 31%[49] - Total cash inflow from financing activities reached ¥547,286,699.42, compared to ¥166,664,982.81 in the previous year, indicating a year-over-year increase of about 228%[50] - The net cash flow from investing activities was -¥12,240,749.57, showing a decrease from -¥13,621,335.43 in Q1 2019, which represents an improvement of approximately 10%[50] - The company reported a net increase in cash and cash equivalents of ¥338,480,992.79 for Q1 2020, compared to ¥83,850,764.34 in Q1 2019, representing a growth of approximately 304%[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,084,879,573.35, an increase of 18.02% from ¥1,766,508,421.42 at the end of the previous year[8] - The total liabilities decreased to CNY 727,961,852.88 from CNY 927,794,163.86, indicating a reduction of 21.5%[37] - The owner's equity increased significantly to CNY 1,415,163,855.17, up from CNY 890,475,813.64, representing a growth of 58.8%[37] - Total liabilities reached CNY 802,209,888.60, with current liabilities at CNY 701,607,329.02 and non-current liabilities at CNY 100,602,559.58[56] - The company has a fixed asset value of CNY 879,359,857.72, indicating substantial investment in long-term assets[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 36,381[12] - The largest shareholder, Hubei Yangtze River Industry Investment Group Co., Ltd., held 16.57% of the shares, totaling 41,710,801 shares[12] Operational Expenses - The company’s sales expenses decreased by 57.42% to 3,152,510.39 due to reduced sales activities[17] - Management expenses increased by 32.73% to 29,017,678.33, primarily due to losses from work stoppages[17] - Research and development expenses for Q1 2020 were CNY 9,272,999.93, slightly up from CNY 9,241,826.79 in the previous year, showing a marginal increase[40] - The financial expenses for Q1 2020 were CNY 6,087,403.73, down from CNY 8,300,908.37 in the previous year, a decrease of approximately 26.7%[40] - The tax expenses for Q1 2020 were CNY 321,703.67, significantly lower than CNY 7,597,553.62 in the previous year, indicating a decrease of about 95.8%[41] Strategic Developments - The company received approval from the China Securities Regulatory Commission for a non-public stock issuance[19] - The company plans to maintain its non-public issuance scheme as approved in the previous shareholder meeting[18] - The company’s Vitamin B6 tablets passed the consistency evaluation, enhancing market competitiveness[18]